Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
14. November 2024 16:05 ET
|
Avenue Therapeutics
MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
09. August 2024 16:05 ET
|
Avenue Therapeutics
- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 – - Raised $4.4 million in gross proceeds...
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
15. Mai 2024 08:30 ET
|
Avenue Therapeutics
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue”...
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
18. März 2024 16:05 ET
|
Avenue Therapeutics
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical...
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
04. Januar 2024 08:30 ET
|
Avenue Therapeutics
MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
13. November 2023 16:05 ET
|
Avenue Therapeutics
- Phase 1b/2a clinical trial of AJ201 remains on track to report topline data in second quarter of 2024 - - Positive BAER-101 preclinical data accepted for presentation at American Epilepsy Society...
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
25. Juli 2023 08:30 ET
|
Avenue Therapeutics
MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
12. Mai 2023 08:30 ET
|
Avenue Therapeutics
MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
17. April 2023 16:01 ET
|
Avenue Therapeutics
MIAMI, April 17, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
30. März 2023 16:01 ET
|
Avenue Therapeutics
MIAMI, March 30, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...